Stina Söderlund1, Lisa Christiansson2, Inger Persson3, Henrik Hjorth-Hansen4, Johan Richter5, Bengt Simonsson6, Satu Mustjoki7, Ulla Olsson-Strömberg8, Angelica Loskog2. 1. Dept. of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Dept. of Medical Sciences, Uppsala University, Uppsala, Sweden; Section of Hematology, Uppsala University Hospital, Uppsala, Sweden. Electronic address: stina.soderlund@igp.uu.se. 2. Dept. of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. 3. Dept. of Statistics, Uppsala University, Uppsala, Sweden. 4. Department of Hematology, St. Olav's Hospital, Trondheim, Norway; Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. 5. Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 6. Dept. of Medical Sciences, Uppsala University, Uppsala, Sweden. 7. Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland; Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. 8. Dept. of Medical Sciences, Uppsala University, Uppsala, Sweden; Section of Hematology, Uppsala University Hospital, Uppsala, Sweden.
Abstract
BACKGROUND AND AIMS: The simultaneous measurement of many proteins is now possible using multiplex assays. In this pilot study we investigated a total of 124 proteins in plasma from chronic myeloid leukemia (CML) patients with the purpose of identifying proteins that are differently expressed at diagnosis and after tyrosine kinase inhibitor (TKI) treatment initiation. METHODS: Samples were taken from 14 CML patients at diagnosis and after three months of TKI treatment (imatinib or dasatinib). Samples were analyzed by Mesoscale Discovery, Myriad RBM MAP technology and Olink Proseek. RESULTS: Multiple plasma proteins were differentially expressed before and after initiation of TKI therapy. Protein patterns demonstrated a possible shift towards Th1-immunity and reduced angiogenic stimuli. Further, some plasma proteins were identified that can be of potential interest to study further for biologic, prognostic or therapeutic significance such as E-selectin, uPAR, growth hormone and carbonic anhydrase IX. CONCLUSIONS: Plasma proteomics seems feasible and useful in CML patients, both for studying patterns of protein expression and for identifying single proteins differentially expressed before and after treatment. Plasma proteomics may be useful to map disease activity and biological processes. Hence, plasma proteomics can be used to understand drug mechanisms and treatment responses in CML.
BACKGROUND AND AIMS: The simultaneous measurement of many proteins is now possible using multiplex assays. In this pilot study we investigated a total of 124 proteins in plasma from chronic myeloid leukemia (CML) patients with the purpose of identifying proteins that are differently expressed at diagnosis and after tyrosine kinase inhibitor (TKI) treatment initiation. METHODS: Samples were taken from 14 CMLpatients at diagnosis and after three months of TKI treatment (imatinib or dasatinib). Samples were analyzed by Mesoscale Discovery, Myriad RBM MAP technology and Olink Proseek. RESULTS: Multiple plasma proteins were differentially expressed before and after initiation of TKI therapy. Protein patterns demonstrated a possible shift towards Th1-immunity and reduced angiogenic stimuli. Further, some plasma proteins were identified that can be of potential interest to study further for biologic, prognostic or therapeutic significance such as E-selectin, uPAR, growth hormone and carbonic anhydrase IX. CONCLUSIONS: Plasma proteomics seems feasible and useful in CMLpatients, both for studying patterns of protein expression and for identifying single proteins differentially expressed before and after treatment. Plasma proteomics may be useful to map disease activity and biological processes. Hence, plasma proteomics can be used to understand drug mechanisms and treatment responses in CML.
Authors: R Bissonnette; C Maari; S Forman; N Bhatia; M Lee; J Fowler; S Tyring; D Pariser; H Sofen; S Dhawan; M Zook; D J Zammit; H Usansky; L Denis; N Rao; T Song; A B Pavel; E Guttman-Yassky Journal: Br J Dermatol Date: 2019-05-06 Impact factor: 9.302
Authors: Katharina Rindler; Thomas Krausgruber; Felix M Thaler; Natalia Alkon; Christine Bangert; Harald Kurz; Nikolaus Fortelny; Thomas B Rojahn; Constanze Jonak; Johannes Griss; Christoph Bock; Patrick M Brunner Journal: Front Immunol Date: 2021-02-24 Impact factor: 7.561
Authors: Ana B Pavel; Jacob W Glickman; James R Michels; Seunghee Kim-Schulze; Rachel L Miller; Emma Guttman-Yassky Journal: Front Genet Date: 2021-07-16 Impact factor: 4.599